Palvella Therapeutics (PVLA) Set to Release Earnings on Thursday

Palvella Therapeutics (NASDAQ:PVLA) will likely be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Palvella Therapeutics to post earnings of ($1.72) per share and revenue of $0.02 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). On average, analysts expect Palvella Therapeutics to post ($6.45) EPS for the current fiscal year and ($8.61) EPS for the next fiscal year.

Palvella Therapeutics Trading Up 3.5%

Shares of Palvella Therapeutics stock traded up $5.17 during mid-day trading on Tuesday, reaching $151.50. 73,944 shares of the stock were exchanged, compared to its average volume of 259,031. The company has a market cap of $2.18 billion, a price-to-earnings ratio of -31.39 and a beta of -0.27. The firm has a 50-day simple moving average of $141.55 and a 200 day simple moving average of $126.92. Palvella Therapeutics has a fifty-two week low of $71.55 and a fifty-two week high of $161.38.

Wall Street Analyst Weigh In

PVLA has been the subject of several recent analyst reports. Canaccord Genuity Group set a $232.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Chardan Capital reissued a “buy” rating and issued a $240.00 target price on shares of Palvella Therapeutics in a report on Wednesday, October 28th. HC Wainwright restated a “buy” rating on shares of Palvella Therapeutics in a research report on Tuesday, October 20th. Raymond James Financial set a $226.00 price objective on Palvella Therapeutics in a research report on Friday, October 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $209.79.

Insider Transactions at Palvella Therapeutics

In other news, Director George Jenkins sold 13,352 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $151.96, for a total transaction of $2,028,969.92. Following the sale, the director directly owned 161,893 shares of the company’s stock, valued at $24,601,260.28. This represents a 7.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher Kiritsy sold 313 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $157.00, for a total transaction of $49,141.00. Following the completion of the sale, the director directly owned 250 shares of the company’s stock, valued at approximately $39,250. This represents a 55.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 61,056 shares of company stock worth $8,756,946. Corporate insiders own 17.20% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.